Melflufen Shows Positive Response in Triple-refractory Multiple Myeloma Trial
Topline results show a 26% response rate in a Phase 2 clinical trial evaluating melflufen (melphalan fluf...
Read moreResearch & Access Updates
Myeloma Canada Research Network Consensus Guideline Consortium (MCRN-CGC)
What was the role of Myeloma Canada in creating these guidelines? Myeloma Canada provided logistic and...
Read moreApproval of Daratumumab in Combination with Lenalidomide and Dexamethasone for Newly Diagnosed Patients Who Are Transplant Ineligible
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that Health Canada recently approved ...
Read moreNew CAR T-cell Clinical Trials in the United States Have Extended Enrollment to Canadian Myeloma Patients!
We are seeing some very promising results with Chimeric antigen receptor (CAR) T-cell therapy in early ph...
Read moreNew Drug Reimbursement Recommendation for Pomalyst
The Canadian Agency for Drugs and Technologies in Health recommanded the reimbursement for Pomalidomide (...
Read moreThe 10th Edition of the Myeloma Canada Scientific Roundtable was a Great Success
On October 4th and 5th, leading hematologists and myeloma researchers from around the country and the Uni...
Read more